ArticleJournal of thoracic disease2025
Construction of a radiogenomics predictive model for KRAS mutation status in patients with non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) represents a significant portion of lung cancer cases globally, with kirsten rats arcomaviral oncogene homolog (KRAS) mutations being a critical factor in its pathogenesis. Predicting KRAS mutation status is crucial for guiding targeted therapies and improving patient outcomes. This study aimed to develop and validate a differential evolution optimized artificial neural network (DE-ANN) model that integrates positron emission tomography/computed tomography (PET/CT) radiomics and genomics data for predicting KRAS mutation status in NSCLC patients, showcasing the potential of multi-omics integration in precision oncology. Methods: The study utilized PET/CT radiomics features and genomics data from public databases using least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) to identify key predictive features. The DE-ANN model was optimized using differential evolution algorithms and validated internally using Bootstrap resampling to assess its predictive performance. Results: The DE-ANN model demonstrated superior predictive accuracy with an area under the curve (AUC) of 0.909 [95% confidence interval (CI): 0.882-0.937], outperforming traditional artificial neural network (ANN) models (AUC =0.819, 95% CI: 0.778-0.860). Key features identified included significant radiomics signatures and gene markers, with the model showing enhanced convergence rates and robust internal validation outcomes. The model's calibration and decision curve analyses further confirmed its clinical applicability and potential for improving personalized treatment strategies in NSCLC. Conclusions: The DE-ANN model represents a significant advancement in the predictive modeling of KRAS mutation status in NSCLC, leveraging the synergy between radiomics and genomic data. Its high predictive accuracy and methodological robustness highlight the model's potential as a tool in precision oncology, warranting further external validation and exploration in other cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.